Drug
Apl 130277
Apl 130277: highest development phase Phase 3, developed by Sumitomo Pharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| APL-130277 NCT03391882 | Phase 3 | Motor OFF Episodes Associated With Parkinson's Disease |
| APL-130277 NCT03187301 | Phase 2 | Parkinson's Disease |
Latest
No recent events.
Follow Apl 130277 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.